Skip to main content

How Cadavers Are Breathing New Life into Drug Discovery

A proteomics atlas built from donated human postmortem tissues could help unbury the molecular landscape of healthy bodies.

Written bySneha Khedkar
| 3 min read
A photograph of a human eye next to a Lego-like structure of the eye.
Register for free to listen to this article
Listen with Speechify
0:00
3:00

As a chief technology officer at a biotech venture capital firm, neuroscientist Elizabeth Hudson frequently analyzed industry trends to support portfolio companies. “You learn a ton doing that, and one of the things you learn is that the data landscape is terrible,” said Hudson. “It's voluminous and yet totally inadequate.”

While massive datasets exist for animal models of specific diseases, Hudson noted that data representing healthy human bodies remain scarce. According to her, this is partly because the pharmaceutical industry operates in vertical silos, with companies trying to master all the steps in either prevention, diagnostics, or therapeutics.

“The analogy I like to use is…think about an airline,” she said, noting that airlines have to ace scheduling flight crews, selling tickets, maintaining planes, and advertising. “They can't also be hiring geologists to go drill wells to extract oil to refine into jet fuel.”

Similarly, Hudson argued that biotech companies spend a lot of resources on obtaining data, which could divert their energies from focusing on their core operations.

A photograph of Elizabeth Hudson wearing a white shirt, blue pants, and green jacket. She sits on a chair against a light background.

Elizabeth Hudson is the CEO and founder of Ambitious Bio.

Winni Wintermeyer

This motivated her to found Ambitious Bio to generate original, raw proteomics data from human postmortem tissue samples, which allow researchers to probe at a deeper level compared to samples obtained from living donors. The company recently launched Corpus, the world’s largest healthy human protein atlas. It offers a reference that teams training AI tools can harness to better understand the human body, helping researchers design better biomedical interventions.

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

Postmortem Tissue Proteomics Shines Light on Hidden Protein Targets

The focus on proteomics was deliberate, explained Hudson. Although researchers have a glut of genomics data, “We know very little about the healthy body at the proteomics level,” she said.

The proteomics gap is particularly glaring considering that many drugs target proteins, Hudson said. However, current drug discovery efforts focus on only a fraction of the hundreds of thousands of proteins produced in the human body. “The universe is full of dark matter,” said Hudson. “There's opportunity out there; we just can't see [it].”

To bring this “dark proteome” into the limelight, Hudson and her colleagues turned to postmortem tissue samples from healthy, non-diseased donors. They focused on healthy samples because, “No matter what disease you're treating, you must know what the healthy body looks like, because your drug is not allowed to nuke the healthy body,” explained Hudson.

A photograph of human aortic tissue.

Researchers at Ambitious Bio also carried out mass spectrometry on human aortic tissue to build a reference proteome.

Ambitious Bio

The researchers obtained frozen cadaver tissue samples and subjected multiple tissues from each donor to mass spectrometry. This helped them identify up to 12,000 proteins per tissue sample. This information expanded the Human Protein Atlas—the field’s most commonly used reference—by 56 percent. This means that Corpus offered information on 56 new proteins in each tissue for 100 that were already known. In fact, in all tissue types compared between Corpus and the Human Protein Atlas, the former detected expression of at least one potential drug target that the latter had missed.

Expanding the Reference Landscape

While the researchers only obtain proteomics data at the moment, they eventually plan to expand their datasets. Matching proteomics results with those from RNA sequencing, whole-genome sequencing, histopathology, transcriptomics, biofluids, and electronic health records of each donor can help obtain a fuller picture of their overall health, noted Hudson.

Moreover, the current data are drawn only from healthy, non-diseased donors, which provides a reference for baseline. By next year, Hudson and her colleagues plan on expanding this to enroll diseased donors to obtain insight into how healthy protein landscapes differ from those in diseased states. This could offer clues into disease-specific drug targets, pointing drug discovery companies in directions to pursue investigations with less uncertainty and financial risk.

“There are people waiting for cures right now,” said Hudson. “If we have any hope of providing better products to people faster and at prices that don't bankrupt folks…better data collection is the only route.”

Zooming out, while Hudson noted that Ambitious Bio does not plan to design, develop, or sell drugs, the company’s vision is to offer raw data upon which these discoveries can be built. “We are like the underground sewer [system] without which those skyscrapers don't run, but you never see [us],” said Hudson.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Sneha Khedkar

    Sneha Khedkar is an Assistant Editor at The Scientist. She has a Master’s degree in biochemistry, after which she studied the molecular mechanisms of skin stem cell migration during wound healing as a research fellow at the Institute for Stem Cell Science and Regenerative Medicine in Bangalore, India. She has previously written for Scientific American, New Scientist, and Knowable Magazine, among others.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Illustrated floating metabolites and molecules

Metabolon Verus™ Kit: Metabolomics Profiling Kit

Metabolon
Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics